Which has better valuation and earnings, IVA or NAMS?

NewAmsterdam Pharma has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $5.07M 157.73 -$400.67M N/A N/A NewAmsterdam Pharma $22.50M 157.94 -$203.82M -$1.79 N/A

Does the media refer more to IVA or NAMS?

In the previous week, NewAmsterdam Pharma had 1 more articles in the media than Inventiva. MarketBeat recorded 5 mentions for NewAmsterdam Pharma and 4 mentions for Inventiva. NewAmsterdam Pharma's average media sentiment score of 1.17 beat Inventiva's score of 0.79 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, IVA or CPRX?

Catalyst Pharmaceuticals has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $5.07M 157.73 -$400.67M N/A N/A Catalyst Pharmaceuticals $588.99M 6.52 $214.33M $1.74 18.02

Which has preferable earnings and valuation, IVA or VKTX?

Viking Therapeutics has lower revenue, but higher earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $5.07M 157.73 -$400.67M N/A N/A Viking Therapeutics N/A N/A -$359.64M -$4.14 N/A

Is IVA or VKTX more profitable?

Inventiva's return on equity of 0.00% beat Viking Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Inventiva N/A N/A N/A Viking Therapeutics N/A -71.31% -65.35%

Does the media favor IVA or VKTX?

In the previous week, Viking Therapeutics had 3 more articles in the media than Inventiva. MarketBeat recorded 7 mentions for Viking Therapeutics and 4 mentions for Inventiva. Inventiva's average media sentiment score of 0.79 beat Viking Therapeutics' score of 0.40 indicating that Inventiva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viking Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, IVA or CRNX?

Inventiva has higher earnings, but lower revenue than Crinetics Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $5.07M 157.73 -$400.67M N/A N/A Crinetics Pharmaceuticals $7.70M 472.02 -$465.32M -$5.13 N/A

Does the media refer more to IVA or CRNX?

In the previous week, Crinetics Pharmaceuticals had 8 more articles in the media than Inventiva. MarketBeat recorded 12 mentions for Crinetics Pharmaceuticals and 4 mentions for Inventiva. Crinetics Pharmaceuticals' average media sentiment score of 1.13 beat Inventiva's score of 0.79 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crinetics Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, KNSA or IVA?

Kiniksa Pharmaceuticals International has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kiniksa Pharmaceuticals International $677.56M 5.89 $59.01M $0.90 57.66 Inventiva $5.07M 157.73 -$400.67M N/A N/A

Inventiva (IVA) Competitors

$3.85 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$3.86 +0.01 (+0.26%)

As of 06/12/2026 04:10 PM Eastern

Compare

IVA vs. NAMS, CPRX, VKTX, CRNX, and KNSA

Should you buy Inventiva stock or one of its competitors? MarketBeat compares Inventiva with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Inventiva include NewAmsterdam Pharma (NAMS), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Crinetics Pharmaceuticals (CRNX), and Kiniksa Pharmaceuticals International (KNSA). These companies are all part of the "pharmaceutical products" industry.

How does Inventiva compare to NewAmsterdam Pharma?

Inventiva (NASDAQ:IVA) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.

Inventiva has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.07, meaning that its share price is 93% less volatile than the broader market.

19.1% of Inventiva shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 32.0% of Inventiva shares are held by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, NewAmsterdam Pharma had 1 more articles in the media than Inventiva. MarketBeat recorded 5 mentions for NewAmsterdam Pharma and 4 mentions for Inventiva. NewAmsterdam Pharma's average media sentiment score of 1.17 beat Inventiva's score of 0.79 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inventiva currently has a consensus target price of $16.56, suggesting a potential upside of 330.01%. NewAmsterdam Pharma has a consensus target price of $48.60, suggesting a potential upside of 59.87%. Given Inventiva's stronger consensus rating and higher possible upside, research analysts plainly believe Inventiva is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Inventiva has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -943.23%. Inventiva's return on equity of 0.00% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

NewAmsterdam Pharma has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	157.73	-$400.67M	N/A	N/A
NewAmsterdam Pharma	$22.50M	157.94	-$203.82M	-$1.79	N/A

Summary

Inventiva beats NewAmsterdam Pharma on 8 of the 15 factors compared between the two stocks.

How does Inventiva compare to Catalyst Pharmaceuticals?

Inventiva (NASDAQ:IVA) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Catalyst Pharmaceuticals has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	157.73	-$400.67M	N/A	N/A
Catalyst Pharmaceuticals	$588.99M	6.52	$214.33M	$1.74	18.02

Inventiva has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

In the previous week, Inventiva had 3 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 4 mentions for Inventiva and 1 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.43 beat Inventiva's score of 0.79 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Inventiva	Positive
Catalyst Pharmaceuticals	Positive

19.1% of Inventiva shares are owned by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 32.0% of Inventiva shares are owned by company insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Inventiva's net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Inventiva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

Inventiva currently has a consensus target price of $16.56, indicating a potential upside of 330.01%. Catalyst Pharmaceuticals has a consensus target price of $32.00, indicating a potential upside of 2.04%. Given Inventiva's stronger consensus rating and higher probable upside, research analysts clearly believe Inventiva is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

Summary

Catalyst Pharmaceuticals beats Inventiva on 8 of the 15 factors compared between the two stocks.

How does Inventiva compare to Viking Therapeutics?

Inventiva (NASDAQ:IVA) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

In the previous week, Viking Therapeutics had 3 more articles in the media than Inventiva. MarketBeat recorded 7 mentions for Viking Therapeutics and 4 mentions for Inventiva. Inventiva's average media sentiment score of 0.79 beat Viking Therapeutics' score of 0.40 indicating that Inventiva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viking Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

19.1% of Inventiva shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 32.0% of Inventiva shares are owned by company insiders. Comparatively, 5.3% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Inventiva presently has a consensus price target of $16.56, suggesting a potential upside of 330.01%. Viking Therapeutics has a consensus price target of $93.60, suggesting a potential upside of 225.57%. Given Inventiva's stronger consensus rating and higher probable upside, research analysts clearly believe Inventiva is more favorable than Viking Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

Viking Therapeutics has lower revenue, but higher earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	157.73	-$400.67M	N/A	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A

Inventiva's return on equity of 0.00% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Viking Therapeutics	N/A	-71.31%	-65.35%

Inventiva has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

Summary

Inventiva beats Viking Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Inventiva compare to Crinetics Pharmaceuticals?

Inventiva (NASDAQ:IVA) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

19.1% of Inventiva shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 32.0% of Inventiva shares are owned by insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Crinetics Pharmaceuticals had 8 more articles in the media than Inventiva. MarketBeat recorded 12 mentions for Crinetics Pharmaceuticals and 4 mentions for Inventiva. Crinetics Pharmaceuticals' average media sentiment score of 1.13 beat Inventiva's score of 0.79 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Crinetics Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inventiva has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

Inventiva currently has a consensus target price of $16.56, suggesting a potential upside of 330.01%. Crinetics Pharmaceuticals has a consensus target price of $76.13, suggesting a potential upside of 120.84%. Given Inventiva's stronger consensus rating and higher possible upside, analysts clearly believe Inventiva is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Crinetics Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Inventiva has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Inventiva's return on equity of 0.00% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%

Inventiva has higher earnings, but lower revenue than Crinetics Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	157.73	-$400.67M	N/A	N/A
Crinetics Pharmaceuticals	$7.70M	472.02	-$465.32M	-$5.13	N/A

Summary

Inventiva beats Crinetics Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Inventiva compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Inventiva (NASDAQ:IVA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. Comparatively, 19.1% of Inventiva shares are held by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Comparatively, 32.0% of Inventiva shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Inventiva had 1 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 4 mentions for Inventiva and 3 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.18 beat Inventiva's score of 0.79 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inventiva	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kiniksa Pharmaceuticals International has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	5.89	$59.01M	$0.90	57.66
Inventiva	$5.07M	157.73	-$400.67M	N/A	N/A

Kiniksa Pharmaceuticals International presently has a consensus price target of $60.86, suggesting a potential upside of 17.28%. Inventiva has a consensus price target of $16.56, suggesting a potential upside of 330.01%. Given Inventiva's stronger consensus rating and higher probable upside, analysts clearly believe Inventiva is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10

Kiniksa Pharmaceuticals International has a beta of 0.12, suggesting that its stock price is 88% less volatile than the broader market. Comparatively, Inventiva has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Inventiva's net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Inventiva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%
Inventiva	N/A	N/A	N/A

Summary

Kiniksa Pharmaceuticals International beats Inventiva on 9 of the 15 factors compared between the two stocks.

Get Inventiva News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IVA vs. The Competition

Export

Metric	Inventiva	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$799.68M	$3.40B	$6.74B	$12.07B
Dividend Yield	N/A	2.25%	2.67%	5.67%
P/E Ratio	N/A	19.82	24.21	24.42
Price / Sales	157.73	305.69	512.04	109.94
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	-17.50	8.32	10.66	6.83
Net Income	-$400.67M	$23.94M	$3.57B	$337.67M
7 Day Performance	-1.53%	1.84%	0.58%	1.17%
1 Month Performance	-29.23%	-0.04%	1.54%	3.16%
1 Year Performance	12.90%	44.82%	25.40%	30.58%

Inventiva Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IVA Inventiva	2.7663 of 5 stars	$3.85 flat	$16.56 +330.0%	+12.9%	$799.68M	$5.07M	N/A	100
NAMS NewAmsterdam Pharma	2.907 of 5 stars	$31.62 -6.1%	$48.00 +51.8%	+50.4%	$3.94B	$22.50M	N/A	4	Positive News
CPRX Catalyst Pharmaceuticals	3.6737 of 5 stars	$31.28 +0.1%	$32.00 +2.3%	+33.3%	$3.82B	$588.99M	17.97	80
VKTX Viking Therapeutics	2.4529 of 5 stars	$29.71 -9.3%	$93.60 +215.1%	+10.2%	$3.80B	N/A	N/A	20
CRNX Crinetics Pharmaceuticals	3.2248 of 5 stars	$32.64 -8.2%	$76.13 +133.2%	+8.5%	$3.75B	$18.07M	N/A	210

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IVA) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inventiva (IVA) Competitors

IVA vs. NAMS, CPRX, VKTX, CRNX, and KNSA

How does Inventiva compare to NewAmsterdam Pharma?

Summary

How does Inventiva compare to Catalyst Pharmaceuticals?

Summary

How does Inventiva compare to Viking Therapeutics?

Summary

How does Inventiva compare to Crinetics Pharmaceuticals?

Summary

How does Inventiva compare to Kiniksa Pharmaceuticals International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVA vs. The Competition

Inventiva Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inventiva (IVA) Competitors

IVA vs. NAMS, CPRX, VKTX, CRNX, and KNSA

How does Inventiva compare to NewAmsterdam Pharma?

Which has more volatility & risk, IVA or NAMS?

Do institutionals and insiders have more ownership in IVA or NAMS?

Does the media refer more to IVA or NAMS?

Do analysts recommend IVA or NAMS?

Is IVA or NAMS more profitable?

Which has better valuation and earnings, IVA or NAMS?

Summary

How does Inventiva compare to Catalyst Pharmaceuticals?

Which has higher earnings & valuation, IVA or CPRX?

Which has more volatility & risk, IVA or CPRX?

Does the media refer more to IVA or CPRX?

Do insiders & institutionals hold more shares of IVA or CPRX?

Is IVA or CPRX more profitable?

Do analysts rate IVA or CPRX?

Summary

How does Inventiva compare to Viking Therapeutics?

Does the media favor IVA or VKTX?

Do insiders and institutionals have more ownership in IVA or VKTX?

Do analysts prefer IVA or VKTX?

Which has preferable earnings and valuation, IVA or VKTX?

Is IVA or VKTX more profitable?

Which has more volatility & risk, IVA or VKTX?

Summary

How does Inventiva compare to Crinetics Pharmaceuticals?

Do insiders & institutionals have more ownership in IVA or CRNX?

Does the media refer more to IVA or CRNX?

Which has more risk and volatility, IVA or CRNX?

Do analysts prefer IVA or CRNX?

Is IVA or CRNX more profitable?

Which has stronger valuation and earnings, IVA or CRNX?

Summary

How does Inventiva compare to Kiniksa Pharmaceuticals International?

Do insiders and institutionals have more ownership in KNSA or IVA?

Does the media prefer KNSA or IVA?

Which has better earnings and valuation, KNSA or IVA?

Do analysts recommend KNSA or IVA?

Which has more risk and volatility, KNSA or IVA?

Is KNSA or IVA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVA vs. The Competition

Inventiva Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools